N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: Examples of 68Ga-and 64Cu-labeled peptides for PET imaging

Journal of Nuclear Medicine

Volumn 55, Issue 10, 2014, Pages 1719-1725

  Gourni, Eleni ^a,b   Mansi, Rosalba ^b,c   Jamous, Mazen ^c   Waser, Beatrice ^d   Smerling, Christiane ^e   Burian, Antje ^e   Buchegger, Franz ^f   Reubi, Jean Claude ^d   Maecke, Helmut R ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e 63B Pharmaceuticals   (Germany)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

64Cu; 68Ga; Gastrin releasing peptide receptor antagonists; PET imaging

Indexed keywords

ALANINE; BOMBESIN; COPPER 64; GALLIUM 68; GASTRIN RELEASING PEPTIDE DERIVATIVE; GASTRIN RELEASING PEPTIDE RECEPTOR; GLUTAMINE; GLYCINE; HISTIDINE; LEUCINE; PEPTIDE HORMONE RECEPTOR BLOCKING AGENT; PHENYLALANINE; RADIOLIGAND; TRACER; TRYPTOPHAN; VALINE; 1,4,7-TRIAZACYCLONONANE-N,N',N''-TRIACETIC ACID; 1-(1,3-CARBOXYPROPYL)-4,7-CARBOXYMETHYL-1,4,7-TRIAZACYCLONONANE; ACETIC ACID DERIVATIVE; BOMBESIN RECEPTOR; CALCIUM; COPPER; GALLIUM; HETEROCYCLIC COMPOUND; PEPTIDE; RADIOPHARMACEUTICAL AGENT; SINGLE HETEROCYCLIC RINGS;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PANCREAS; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEIN TARGETING; RECEPTOR AFFINITY; ROOM TEMPERATURE; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CHEMISTRY; IC50; PATHOLOGY; PROCEDURES; SCINTISCANNING;

ACETATES; ANIMALS; BOMBESIN; CALCIUM; COPPER RADIOISOTOPES; GALLIUM RADIOISOTOPES; HETEROCYCLIC COMPOUNDS; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INHIBITORY CONCENTRATION 50; MICE; NEOPLASM TRANSPLANTATION; PANCREAS; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, BOMBESIN;

EID: 84907529197     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.141242     Document Type: Article

References (40)

1. Lee S, Xie J, Chen X. Peptides and peptide hormones for molecular imaging and diseases diagnosis. Chem Rev. 2010;110:3087-3111.
2. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389-427.
3. Schroeder RPJ, van Weeden WM, Bangma C, Krenning EP, de Jong M. Peptide receptor imaging of prostate cancer with radiolabeled bombesin analogues. Methods. 2009;48:200-204.
4. Bodei L, Ferrari M, Nunn AD, et al. 177Lu-AMBA bombesin analogue in hormone refractory prostate cancer patients: a phase I escalation study with single-cycle administrations [abstract]. Eur J Nucl Med Mol Imaging. 2007;34(suppl 2):S221.
5. Casanueva FF, Perez FR, Casabiell X, Camina JP, Cai RZ, Schally AV. Correlation between the effects of bombesin antagonists on cell proliferation and intracellular calcium concentration in Swiss 3T3 and HT-29 cell lines. Proc Natl Acad Sci USA. 1996;93:1406-1411.
6. Ginj M, Zhang H, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA. 2006;103:16436-16441.
7. Cescato R, Maina T, Nock B, et al. Bombesin receptor antagoists may be preferable to agonists for tumor targeting. J Nucl Med. 2008;49:318-326.
8. Mansi R, Wang X, Forrer F, et al. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res. 2009;15: 5240-5249.
9. Mansi R, Wang X, Forrer F, et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRP-r-positive tumors. Eur J Nucl Med Mol Imaging. 2011;38:97-107.
10. Abiraj K, Mansi R, Tamma ML, et al. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. J Nucl Med. 2011;52:1970-1978.
11. Wieser G, Mansi R, Grosu AL, et al. Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist-from mice to men. Theranostics. 2014;4:412-419.
12. Llinares M, Devin C, Chaloin O, et al. Synthesis and biological activities of potent bombesin receptor antagonists. J Pept Res. 1999;53:275-283.
13. Atherton E. Fluorenylmethoxycarbonyl-Polyamide Solid Phase Peptide Synthesis: General Principles and Development. Oxford, U.K.: Oxford Information Press; 1989:25-38.
14. Markwalder R, Reubi JC. Gastrin-releasing peptides receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 1999;59:1152-1159.
15. Mansi R, Fleischmann A, Maecke HR, Reubi JC. Targeting GRPR in urological cancers-from basic research to clinical application. Nat Rev Urol. 2013;10:235-244.
16. Zhang H, Abiraj K, Thorek DLJ, et al. Evolution of bombesin conjugates for targeted PET imaging of tumors. PLoS ONE. 2012;7:e44046.
17. Zhang H, Chen J, Waldherr C, et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res. 2004;64:6707-6715.
18. Nock BA, Nikolopoulou A, Galanis A, et al. Potent bombesin-like peptides for GRP receptor targeting of tumors with 99mTc: a preclinical study. J Med Chem. 2005;48:100-110.
19. Bergmann R, Ruffani A, Graham B, et al. Synthesis and radiopharmacological evaluation of 64Cu-labeled bombesin analogs featuring a bis(2-pyridylmethyl)-1,4,7-triazacyclononane chelator. Eur J Med Chem. 2013;70:434-446.
20. Yang Y-S, Zhang X, Xiong Z, Chen X. Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl Med Biol. 2006;33:371-380.
21. Dijkgraaf I, Franssen GM, McBride WJ, et al. PET of tumors expressing gastrinreleasing peptide receptor with an 18F-labeled bombesin analog. J Nucl Med. 2012;53:947-952.
22. Liu Z, Li Z-B, Cao Q, Liu S, Wang F, Chen X. Small-animal PET of tumors with 64Cu-labeled RGD-bombesin heterodimer. J Nucl Med. 2009;50:1168-1177.
23. Zhou Z, Wagh NK, Ogbomo SM, et al. Synthesis and in vitro and in vivo evaluation of hypoxia-enhanced 111In-bombesin conjugates for prostate cancer imaging. J Nucl Med. 2013;54:1605-1612.
24. Durkan K, Zongrum J, Rold TL, et al. A heterodimeric [RGD-Glu[64Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors. Nucl Med Biol. 2014;41:133-139.
25. Jackson AB, Nanda PK, Rold TL, et al. 64Cu-NO2A-RGD-Glu-6-Ahx-BBN(7-14)NH2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer. Nucl Med Biol. 2012;39:377-387.
26. Fani M, Del Pozzo L, Abiraj K, et al. PET of somatostatin receptor-positive tumors using 64Cu-and 68Ga-somatostatin antagonists: the chelate makes the difference. J Nucl Med. 2011;52:1110-1118.
27. Wadas TJ, Eiblmaier M, Zheleznyak A, et al. Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors. J Nucl Med. 2008;49:1819-1827.
28. Wild D, Fani M, Behe M, et al. First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J Nucl Med. 2011;52:1412-1417.
29. Abd-Elgaliel WR, Gallazzi F, Garrison JC, et al. Design, synthesis and biological evaluation of an antagonist-bombesin analogue as targeting vector. Bioconjug Chem. 2008;19:2040-2048.
30. Marsouvanidis PJ, Nock BA, Hajjaj B, et al. Gastrin releasing peptide receptordirected radioligands based on a bombesin antagonist: synthesis, 111In-labeling, and preclinical profile. J Med Chem. 2013;56:2374-2384.
31. Liu Y, Hu X, Liu H, et al. A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer. J Nucl Med. 2013;54:2132-2138.
32. Varasteh Z, Velikyan I, Lindeberg G, et al. Synthesis and characterization of a high-affinity NOTA-conjugate bombesin antagonist for GRPR-targeted tumor imaging. Bioconjug Chem. 2013;24:1144-1153.
33. Yang M, Gao H, Zhou Y, et al. 18F-labeled agonists and antagonists: a comparative study in prostate cancer imaging. Theranostics. 2011;1:220-229.
34. Nanda PK, Wienhoff BE, Rold TL, et al. Positron-emission tomography (PET) imaging agents for diagnosis of human prostate cancer: agonist vs. antagonist ligands. In Vivo. 2012;26:583-592.
35. Roivainen A, Kähkönen E, Luoto P, et al. Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men. J Nucl Med. 2013;54:867-872.
36. Kähkönen E, Jambor I, Kemppainen J, et al. In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY68-7548. Clin Cancer Res. 2013; 19:5434-5443.
37. Lears KA, Ferdani R, Liang K, et al. In vitro and in vivo evaluation of 64Culabeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer. J Nucl Med. 2011;52:470-477.
38. Roesch F, Riss PJ. The renaissance of the 68Ge/68Ga radionuclide generator initiates new developments in 68Ga radiopharmaceutical chemistry. Curr Top Med Chem. 2010;10:1633-1668.
39. Anderson CJ, Ferdani R. Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. Cancer Biother Radiopharm. 2009;24:379-393.
40. Prasanphanich AF, Nanda PK, Rold TL, et al. [64Cu-NOTA-8-Aoc-BBN(7-14) NH2] targeting vector for positron-emission tomography imaging of gastrinreleasing peptide receptor-expressing tissues. Proc Natl Acad Sci USA. 2007;104:12462-12467.